ArticleMedicine2026
Co-infection of cytomegalovirus and Epstein-Barr virus-induced pneumonitis following hepatitis B reactivation in an esophageal cancer patient: A case report.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleCytomegalovirus (CMV) and/or Epstein-Barr virus (EBV) infection or reactivation is widely recognized in immunocompromised individuals, particularly those undergoing transplantation or those with acquired immune deficiency syndrome. There are reports of EBV-CMV co-infection or reactivation; however, this co-infection-induced pneumonitis has rarely been seen in patients outside these settings. PATIENT CONCERNS: A 64-year-old male with previously treated pulmonary tuberculosis, positive hepatitis B surface antigen and a squamous cell carcinoma of the esophagus underwent 5 cycles of concurrent radiochemotherapy with weekly carboplatin and paclitaxel. Following treatment completion, the patient developed reactivated hepatitis B, requiring antiviral therapy initiation. Six weeks after completing radiochemotherapy, the patient experienced fever and dyspnea. DIAGNOSES: The initial chest computed tomography scan revealed honeycomb-like, triangular, mixed alveolar-interstitial opacification in both lungs. Due to a poor clinical response to empiric antibiotics and negative results for both blood and sputum cultures, a bronchoalveolar lavage sample was obtained and revealed high viral loads of EBV and CMV, suggesting EBV-CMV pneumonitis.
interventionsTreatment with ganciclovir and corticosteroids resulted in significant clinical improvement, with marked resolution of lesions observed on computed tomography scans. OUTCOMES: The patient was discharged in stable condition. However, 4 weeks later, while still on corticosteroid taper, the patient developed a recurrence of fever that progressed to respiratory failure, and was subsequently diagnosed with respiratory aspergillosis. The patient passed away after 1 week. LESSONS: This case highlights the importance of suspecting CMV and/or EBV pneumonitis in patients undergoing chemotherapy and no response to empiric antibiotics. Timely detection of causative pathogens is important, as prompt intervention can markedly improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.